Cantor Fitzgerald Reiterates Overweight on Sanara MedTech, Maintains $59 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Brandon Folkes has reiterated an Overweight rating on Sanara MedTech (NASDAQ:SMTI) and maintained a $59 price target.
August 17, 2023 | 3:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Sanara MedTech and maintained a $59 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Sanara MedTech. This could potentially lead to an increase in the stock's price in the short term. The maintained price target of $59 also suggests that the analyst believes the stock is currently undervalued, which could attract more investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100